Abstract:Despite effective new therapies, adaptive resistance remains the main obstacle in acute myelogenous leukemia (AML) therapy. Autophagy induction is a key mechanism for adaptive resistance. Leukemic blasts at diagnosis express higher levels of the apical autophagy kinase ULK1 compared with normal hematopoietic cells. Exposure to chemotherapy and targeted agents upregulate ULK1, hence we hypothesize that developing ULK1 inhibitors may present the unique opportunity for clinical translation of autophagy inhibition. Accordingly, we demonstrate that ULK1 inhibition, by genetic and pharmacologic means, suppresses treatment-induced autophagy, overcomes adaptive drug-resistance, and synergizes with chemotherapy and emerging antileukemia agents like venetoclax (ABT-199). The study next aims at exploring the underlying mechanisms. Mechanistically, ULK1 inhibition downregulates MCL1 antiapoptotic gene, impairs mitochondrial function and downregulates components of the CD44-xCT system, resulting in impaired reactive oxygen species (ROS) mitigation, DNA damage, and apoptosis. For further validation, several mouse models of AML were generated. In these mouse models, ULK1 deficiency impaired leukemic cell homing and engraftment, delayed disease progression, and improved survival. Therefore, in the study, we validated our hypothesis and identified ULK1 as an important mediator of adaptive resistance to therapy and an ideal candidate for combination therapy in AML. Therefore, we propose ULK1 inhibition as a therapeutically relevant treatment option to overcome adaptive drug-resistance in AML. Implications: ULK1 drives a cell-intrinsic adaptive resistance in AML and targeting ULK1-mediated autophagy can synergize with existing and emerging AML therapies to overcome drug-resistance and induce apoptosis.

UNC-51-like Kinase 1: from an Autophagic Initiator to Multifunctional Drug Target

UNC51-like kinase 1, autophagic regulator and cancer therapeutic target.

Phosphorylation of ULK1 Affects Autophagosome Fusion and Links Chaperone-Mediated Autophagy to Macroautophagy

The mechanism of UNC-51-like kinase 1 and the applications of small molecule modulators in cancer treatment

Ulk1 Can Suppress Or Promote Tumor Growth Under Different Conditions

A patent review of UNC-51-like kinase 1/2 inhibitors (2019–present)

Physiological functions of ULK1/2

The Crucial Role of the Regulatory Mechanism of the Atg1/ULK1 Complex in Fungi

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

Targeting Autophagy-Related Protein Kinases for Potential Therapeutic Purpose

A small-molecule activator of UNC-51-like kinase 1 (ULK1) that induces cytoprotective autophagy for Parkinson's disease treatment.

In Silico Approaches for the Identification of Novel ULK1 Inhibitors: Pharmacophore Model, Molecular Docking and Molecular Dynamics Simulations

Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties

A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer

Serine/Threonine Kinase Unc-51-like Kinase-1 (ulk1) Phosphorylates the Co-chaperone Cell Division Cycle Protein 37 (cdc37) and Thereby Disrupts the Stability of Cdc37 Client Proteins

ULK1-ATG13 and Their Mitotic Phospho-Regulation by CDK1 Connect Autophagy to Cell Cycle

Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Phospho-regulation and function of ULK1-ATG13 during the cell cycle

CDK1 phosphorylates ULK1-ATG13 complex to regulate mitotic autophagy and Taxol chemosensitivity

ULK1 as a therapeutic target in kidney diseases: Current perspective

Effect of Molecular Weight and Charge Ratio on the Stability of the Chitosan/dna Complexes